PMID- 32526706
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Jun 10
TI  - ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug 
      resistance of multiple myeloma cells by up-regulating CDC5L.
PG  - 11100-11115
LID - 10.18632/aging.103326 [doi]
AB  - This study aimed to investigate whether annexin A7 (ANXA7) could promote the cell 
      cycle, proliferation and cell adhesion-mediated drug resistance (CAM-DR) of 
      multiple myeloma (MM) cells by up-regulating cell division cycle 5-like (CDC5L). 
      As a result, ANXA7 expression was increased in the serum of MM patients and the 
      expression of ANXA7 and CDC5L was also increased in MM cell lines. ANXA7 
      overexpression promoted the proliferation and cycle of U266 and RPMI8226 cells. 
      The expression of proliferation cell nuclear antigen (PCNA), KI67, cyclin 
      dependent kinase 1 (CDK1) and cyclinB1 in transfected cells was consistent with 
      the changes of proliferation and cell cycle. In co-culture system of BMSC cells 
      and MM cells, expression of CD44, ICAM1 and VCAM1 in MM cells was increased, 
      which was further increased by ANXA7 overexpression. Bortezomib could increase 
      the apoptosis of U266 and RPMI8226 cells. In co-culture system of BMSC cells and 
      MM cells, the promotion effects of bortezomib on apoptosis of MM cells was 
      decreased, which was further suppressed by ANXA7 overexpression. The above 
      effects exerted by ANXA7 overexpression could be reversed by ANXA7 interference. 
      Moreover, ANXA7 was proved to be combined with CDC5L. CDC5L interference could 
      inhibit the promotion effects of ANXA7 overexpression on proliferation and cell 
      cycle and inhibition effects of ANXA7 overexpression on apoptosis of MM cells 
      treated with bortezomib in co-culture system. In conclusion, ANXA7 could promote 
      the cell cycle, proliferation and CAM-DR of MM cells by up-regulating CDC5L.
FAU - Liu, Haiyan
AU  - Liu H
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Guo, Dan
AU  - Guo D
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Sha, Yuou
AU  - Sha Y
AD  - School of Basic Medicine, Tongji Medical College, Huazhong University of Science 
      and Technology, Wuhan 430030, China.
FAU - Zhang, Chenlu
AU  - Zhang C
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Jiang, Yijing
AU  - Jiang Y
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Hong, Lemin
AU  - Hong L
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Jiang, Yuwen
AU  - Jiang Y
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Lu, Ling
AU  - Lu L
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Huang, Hongming
AU  - Huang H
AD  - Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 
      226001, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200610
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Annexin A7)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CDC5L protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Annexin A7/*metabolism
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - Bortezomib/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Cycle Proteins/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Coculture Techniques
MH  - *Drug Resistance, Neoplasm
MH  - Humans
MH  - Multiple Myeloma/drug therapy/*metabolism
MH  - RNA-Binding Proteins/*metabolism
MH  - Up-Regulation
PMC - PMC7346058
OTO - NOTNLM
OT  - ANXA7
OT  - CDC5L
OT  - cell cycle
OT  - drug resistance
OT  - multiple myeloma
COIS- CONFLICTS OF INTEREST: The authors declare they have no conflicts of interest.
EDAT- 2020/06/12 06:00
MHDA- 2021/02/25 06:00
PMCR- 2020/06/15
CRDT- 2020/06/12 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/15 00:00 [pmc-release]
AID - 103326 [pii]
AID - 10.18632/aging.103326 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2020 Jun 10;12(11):11100-11115. doi: 10.18632/aging.103326. 
      Epub 2020 Jun 10.